PMA device
Atellica IM free PSA II (fPSAII)
Siemens Healthcare Diagnostics, Inc. · Test, Prostate Specific Antigen, Free, (Noncomplexed) To Distinguish Prostate Cancer From Benign Conditions (MTG, Class III) · First FDA decision May 11, 2026, newest May 11, 2026Prostate cancer
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
0
Naming "Atellica IM"
MAUDE reports
2,244
Brand "Atellica IM", since 2015
PubMed studies
71
Mentioning "Atellica IM"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Atellica IM free PSA II (fPSAII)
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
P250026 · Decided May 11, 2026 · 297 days after receipt
Device type: Test, prostate specific antigen, free, (noncomplexed) to distinguish prostate cancer from benign conditions (MTG) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Prostate Specific Antigen (Addition of ICD-9-CM 600.00, Hypertrophy (benign) of Prostate Without Urinary Obstruction, as a covered indication)Coding analysisReview closedCAG-00326NUpdated Sep 15, 2026
- Prostate Specific AntigenNational determinationOn the books190.31Updated Oct 1, 2026
- Prostate Specific Antigen (Inclusion of ICD-9-CM Code 600.01 for BPH with Urine Obstruction)Coding analysisReview closedCAG-00232NUpdated Sep 15, 2026
- Autologous Cellular Immunotherapy Treatment of Metastatic Prostate CancerNational analysisReview closedCAG-00422NUpdated Nov 19, 2026
- Abarelix for the Treatment of Prostate CancerNational analysisReview closedCAG-00238NUpdated Sep 15, 2026
- PSA (Addition of ICD-9-CM 600.21, Benign localized hyperplasia of prostate with urinary obstruction as a covered indication)Coding analysisReview closedCAG-00332NUpdated Sep 15, 2026
- Cryosurgical Salvage Therapy for Recurrent Prostate CancerNational analysisReview closedCAG-00064NUpdated Sep 14, 2026
- Cryosurgery Ablation for Prostate CancerNational analysisReview closedCAG-00031NUpdated Sep 14, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Atellica IM", any status and sponsor, newest update first.
No registered device study names "Atellica IM".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Atellica IM", and for the whole product code for context.
This brand
2,244 reports: 2,229 malfunction, 15 injury, 0 death
Whole product code MTG
108 reports: 107 malfunction, 1 injury, 0 death
Newest reports for this brand
Siemens Healthcare Diagnostics, Inc.
1219913-2026-00202 · Received Oct 30, 2026 · Event dated Oct 27, 2026
Device type: Immunoassay Method, Troponin Subunit (MMI)
Device problem as coded: High Test Results
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- Atellica IM Alpha Fetoprotein (AFP)Malfunction
Siemens Healthcare Diagnostics, Inc.
1219913-2026-00201 · Received Oct 28, 2026 · Event dated Sep 23, 2026
Device type: Kit, Test, Alpha-Fetoprotein For Neural Tube Defects (LOK)
Device problem as coded: Low Test Results
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- Atellica IMMalfunction
Siemens Healthcare Diagnostics Inc.
1219913-2026-00200 · Received Oct 27, 2026 · Event dated Sep 21, 2026
Device type: Radioassay, Vitamin B12 (CDD)
Device problem as coded: High Test Results
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Atellica IM"[tiab]. The summary above synthesizes these.
- Vitamin B12 reference intervals.
Andersen SL, Hansen AB, Hindersson P, et al. · Dan Med J · 2023
- Head-to-head comparison of four plasma neurofilament light chain (NfL) immunoassays.
Ashrafzadeh-Kian S, Figdore D, Larson B, et al. · Clin Chim Acta · 2024Comparative Study
- Evaluation of Siemens Atellica AMH assay and comparison with Roche, Beckman and Ansh Labs.
Shang E, Agustin H, Lee JKY, et al. · Clin Biochem · 2025Comparative Study, Evaluation Study
- Hook effect although rare, still exists.
Napoli G, Leggeri S, Lombardi C, et al. · Clin Biochem · 2025Case Reports
- Performance evaluation of Siemens Atellica enhanced estradiol assay.
Macias-Muñoz L, Filella X, Augé JM, et al. · Adv Lab Med · 2020
- Biological variation estimates for serum neurofilament light chain in healthy subjects.
Carobene A, Maiese K, Abou-Diwan C, et al. · Clin Chim Acta · 2023
- Standardization of two SARS-CoV-2 serology assays to the WHO 20/136 human standard reference material.
Freeman J, Conklin J · J Virol Methods · 2022Research Support, Non-U.S. Gov't
- Clinical Laboratory Validation Study of a High Sensitivity Troponin I Assay on a POCT (Point of Care Testing) Device.
Pitta FG, Leme AC, Gomes SR, et al. · Glob Heart · 2024Validation Study
- Concordance of Three Automated Procalcitonin Immunoassays at Medical Decision Points.
Cho HW, Kim SH, Cho Y, et al. · Ann Lab Med · 2021
- Analytical performance of the Enhanced Liver Fibrosis (ELF) Test on the Atellica IM Analyzer.
Palladino A, Gee M, Shalhoub V, et al. · Clin Chim Acta · 2023
- Establishment of CA19-9 reference intervals in an apparently healthy adult population in Singapore.
Lee JMY, Teo P, Lam LCW · Ann Clin Biochem · 2024
- Analytical performance comparing siemens whole blood point of care Atellica VTLi to the central laboratory plasma Atellica IM high-sensitivity cardiac troponin I assays.
Xiong-Hang K, Schulz K, Sandoval Y, et al. · Clin Biochem · 2023
Other devices of this type
Also filed under product code MTG.
- Elecsys free PSA, free PSA CalSetRoche Diagnostics Corp. · PMA 2023
- Access Hybritech free PSABeckman Coulter, Inc. · PMA 2025
- ARCHITECT Free PSAAbbott Laboratories · PMA 2020
- Dimension FPSA Flex Reagent CartridgeSiemens Healthcare Diagnostics · PMA 2018
- Dimension Vista Fpsa AssaySiemens Healthcare Diagnostics · PMA 2016
- Axsym Free PsaAbbott Laboratories · PMA 2011
- Immulite/Immulite 1000 & Immulite 2000 Free PsaSiemens Medical Solutions Diagnostics Limited · PMA 2010
- IMMULITE 2000 Free PSASiemens Medical Solutions Diagnostics Limited · PMA 2026
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.